Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic CD56-positive CD3-negative natural killer cells CYNK-001

A population of cryopreserved, off-the-shelf (OTS) allogeneic natural killer (NK) cells derived from human placental hematopoietic stem cells (HSCs) and expressing the CD56 surface antigen and exhibiting a lack of CD3, with potential immunomodulating, antineoplastic and antiviral activities. Upon infusion of allogeneic CD56-positive CD3-negative NK cells CYNK-001, these cells are able to recognize tumor cells as well as virally-infected cells, secrete perforins, granzymes and cytokines, and induce apoptosis in tumor and virally-infected cells.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:allogeneic CD56+/CD3- natural killer cells CYNK-001
allogeneic human placental hematopoietic stem cell-derived natural killer cells CYNK-001
CD56+/CD3- NK cells CYNK-001
human placental HSC-derived CD56+/CD3- NKs CYNK-001
natural killer cells CYNK-001
Code name:CYNK 001
CYNK-001
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search